You bring up a really good point there KBC. Given current managements business accumen managing a sister company makes one wonder how long you would want to hold a company with a CVR deal that could take years to complete. Good food for thought.

On another note, and this is probably better posted on the RVX board, if anyone continued reading the article on Fiercepharma.com that was after the BMS article it confirmed what I have been eluding to as a stumbling block for potential buyers of RVX. The article I'm referring to is titled AACR: AstraZeneca offers first look at Imfinzi.

"Taken at face value, the results from the two trials suggest that Imfinzi’s efficacy in both the neoadjuvant and adjuvant settings compares with Opdivo's in neoadjuvant alone. If this reading proves true, sales prospects for the anti-PD-1/L1 class could take a hit because it would mean patients need shorter treatment periods for positive outcomes.

But in an interview with Fierce Pharma, John Heymach, M.D., Ph.D., chair of MD Anderson Cancer Center’s thoracic/head and neck cancer practice, and lead investigator of the AEGEAN study, cautioned against comparing the two trials directly because of several differences."

Didn't know where to start or finish the quote in order to get the correct context but where it says "sales - - - - - could take a hit" said it all. Can you imagine the potential sales hit that a BP could take on existing products if they put apabetalone on the market? Again just food for thought.

tada